Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti-neutrophil cytoplasmic antibody-associated vasculitis

Kidney Int. 2022 Feb;101(2):414-415. doi: 10.1016/j.kint.2021.11.012. Epub 2021 Nov 22.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / drug therapy
  • Antibodies, Antineutrophil Cytoplasmic
  • Antibody Formation
  • COVID-19 Vaccines
  • COVID-19*
  • Humans
  • Remission Induction
  • Rituximab / adverse effects
  • SARS-CoV-2

Substances

  • Antibodies, Antineutrophil Cytoplasmic
  • COVID-19 Vaccines
  • Rituximab